Literature DB >> 25865049

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.

Eduardo Vilar-Gomez1, Yadina Martinez-Perez2, Luis Calzadilla-Bertot2, Ana Torres-Gonzalez2, Bienvenido Gra-Oramas3, Licet Gonzalez-Fabian3, Scott L Friedman4, Moises Diago5, Manuel Romero-Gomez6.   

Abstract

BACKGROUND & AIMS: It is not clear how weight loss affects histologic features of liver in patients with nonalcoholic steatohepatitis (NASH). We examined the association between the magnitude of weight loss through lifestyle modifications and changes in histologic features of NASH.
METHODS: We conducted a prospective study of 293 patients with histologically proven NASH who were encouraged to adopt recommended lifestyle changes to reduce their weight over 52 weeks, from June 2009 through May 2013, at a tertiary medical center in Havana, Cuba. Liver biopsies were collected when the study began and at week 52 of the diet and were analyzed histologically.
RESULTS: Paired liver biopsies were available from 261 patients. Among 293 patients who underwent lifestyle changes for 52 weeks, 72 (25%) achieved resolution of steatohepatitis, 138 (47%) had reductions in nonalcoholic fatty liver disease activity score (NAS), and 56 (19%) had regression of fibrosis. At week fifty-two, 88 subjects (30%) had lost ≥5% of their weight. Degree of weight loss was independently associated with improvements in all NASH-related histologic parameters (odds ratios = 1.1-2.0; P < .01). A higher proportion of subjects with ≥5% weight loss had NASH resolution (51 of 88 [58%]) and a 2-point reduction in NAS (72 of 88 [82%]) than subjects who lost <5% of their weight (P < .001). All patients who lost ≥10% of their weight had reductions NAS, 90% had resolution of NASH, and 45% had regression of fibrosis. All patients who lost 7%-10% of their weight and had few risk factors also had reduced NAS. In patients with baseline characteristics that included female sex, body mass index ≥35, fasting glucose >5.5 mmol/L, and many ballooned cells, NAS scores decreased significantly with weight reductions ≥10%.
CONCLUSIONS: A greater extent of weight loss, induced by lifestyle changes, is associated with the level of improvement in histologic features of NASH. The highest rates of NAS reduction, NASH resolution, and fibrosis regression occurred in patients with weight losses ≥10%.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BMI; Lifestyle Intervention; NAFLD Activity Score; Resolution of Steatohepatitis

Mesh:

Year:  2015        PMID: 25865049     DOI: 10.1053/j.gastro.2015.04.005

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  432 in total

1.  Lifestyle Interventions Beyond Diet and Exercise for Patients With Nonalcoholic Fatty Liver Disease.

Authors:  James Philip Esteban; Amreen Dinani
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-03

2.  Nonalcoholic Fatty Liver Disease: An Important Consideration for Primary Care Providers in Hawai'i.

Authors:  Robert J Pattison; James Phillip Esteban; Tomoki Sempokuya; Jakrin Kewcharoen; Sumodh Kalathil; Scott K Kuwada
Journal:  Hawaii J Health Soc Welf       Date:  2020-06-01

Review 3.  Genetic and epigenetic mechanisms of NASH.

Authors:  Mohammed Eslam; Jacob George
Journal:  Hepatol Int       Date:  2015-12-18       Impact factor: 6.047

Review 4.  The Effects of Physical Exercise on Fatty Liver Disease.

Authors:  Dirk J van der Windt; Vikas Sud; Hongji Zhang; Allan Tsung; Hai Huang
Journal:  Gene Expr       Date:  2017-12-06

Review 5.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

6.  Targeting Kupffer cells in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why and how?

Authors:  Nicolas Lanthier
Journal:  World J Hepatol       Date:  2015-09-08

7.  Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?

Authors:  Gabriel Tayguara Silveira Guerreiro; Larisse Longo; Mariana Alves Fonseca; Valessa Emanoele Gabriel de Souza; Mário Reis Álvares-da-Silva
Journal:  Hepatol Int       Date:  2021-03-10       Impact factor: 6.047

8.  Non-alcoholic fatty liver disease.

Authors:  Wenhao Li; William Alazawi
Journal:  Clin Med (Lond)       Date:  2020-09       Impact factor: 2.659

9.  Effects of Bariatric Surgery on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Geraldine J Ooi; Paul R Burton; Lisa Doyle; John M Wentworth; Prithi S Bhathal; Ken Sikaris; Michael A Cowley; Stuart K Roberts; William Kemp; Arul Earnest; Paul E O'Brien; Wendy A Brown
Journal:  Obes Surg       Date:  2017-06       Impact factor: 4.129

10.  The Effectiveness of Endoscopic Gastroplasty for Obesity Treatment According to FDA Thresholds: Systematic Review and Meta-Analysis Based on Randomized Controlled Trials.

Authors:  Antonio Coutinho Madruga-Neto; Wanderley Marques Bernardo; Diogo Turiani Hourneaux de Moura; Vitor Ottoboni Brunaldi; Rafael Krieger Martins; Iatagan Rocha Josino; Eduardo Turiani Hourneaux de Moura; Thiago Ferreira de Souza; Marco Aurélio Santo; Eduardo Guimarães Hourneaux de Moura
Journal:  Obes Surg       Date:  2018-09       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.